MX2021011464A - Inhibidor que contiene anticuerpo del receptor anti-interleucina 6 (il-6) para inhibir el deterioro de la funcion de la barrera hemato-encefalica (bbb). - Google Patents

Inhibidor que contiene anticuerpo del receptor anti-interleucina 6 (il-6) para inhibir el deterioro de la funcion de la barrera hemato-encefalica (bbb).

Info

Publication number
MX2021011464A
MX2021011464A MX2021011464A MX2021011464A MX2021011464A MX 2021011464 A MX2021011464 A MX 2021011464A MX 2021011464 A MX2021011464 A MX 2021011464A MX 2021011464 A MX2021011464 A MX 2021011464A MX 2021011464 A MX2021011464 A MX 2021011464A
Authority
MX
Mexico
Prior art keywords
seq
sequence
inhibiting
inhibitor
brain barrier
Prior art date
Application number
MX2021011464A
Other languages
English (en)
Inventor
Yukio Takeshita
Takashi Kanda
Kenichi Serizawa
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of MX2021011464A publication Critical patent/MX2021011464A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención se refiere a supresores de reducción de la función de la barrera hemato-encefálica (BBB), supresores de la disrupción de las uniones herméticas de la barrera hemato-encefálica, supresores de infiltración de leucocitos en el CNS, supresores de permeación de IgGs en la sangre del paciente en el CNS, y agentes terapéuticos para el trastorno del espectro de neuromielitis óptica, enfermedad de neuro-Behcet, neurosarcoidosis, lupus del sistema nervioso central (lupus neuropsiquiátrico), encefalitis autoinmune, o enfermedad de Vogt-Koyonagi-Harada, las cuales suprimen la reducción de la función de la barrera hemato-encefálica y/o restauran la función reducida de la barrera hemato-encefálica, los cuales contienen un anticuerpo que contiene una región variable de cadena pesada que contiene CDR1 que tiene la secuencia de la SEC ID NO: 1, CDR2 que tiene la secuencia de la SEC ID NO: 2, y CDR3 que tiene la secuencia de la SEC ID NO: 3, y una región variable de cadena ligera que contiene CDR1 que tiene la secuencia de la SEC ID NO: 4, CDR2 que tiene la secuencia de la SEC ID NO: 5, y CDR3 que tiene la secuencia de la SEC ID NO: 6.
MX2021011464A 2019-03-29 2020-02-17 Inhibidor que contiene anticuerpo del receptor anti-interleucina 6 (il-6) para inhibir el deterioro de la funcion de la barrera hemato-encefalica (bbb). MX2021011464A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019068693 2019-03-29
PCT/JP2020/005965 WO2020202839A1 (ja) 2019-03-29 2020-02-17 抗ｉｌ－６受容体抗体を含有するｂｂｂ機能低下の抑制剤

Publications (1)

Publication Number Publication Date
MX2021011464A true MX2021011464A (es) 2021-10-22

Family

ID=72667972

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011464A MX2021011464A (es) 2019-03-29 2020-02-17 Inhibidor que contiene anticuerpo del receptor anti-interleucina 6 (il-6) para inhibir el deterioro de la funcion de la barrera hemato-encefalica (bbb).

Country Status (12)

Country Link
US (1) US20220220210A1 (es)
EP (1) EP3949989A4 (es)
JP (1) JPWO2020202839A1 (es)
KR (1) KR20210144795A (es)
CN (1) CN113660951A (es)
AU (1) AU2020255449A1 (es)
BR (1) BR112021017702A2 (es)
CA (1) CA3133610A1 (es)
IL (1) IL286716A (es)
MX (1) MX2021011464A (es)
TW (1) TW202102540A (es)
WO (1) WO2020202839A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018203545A1 (ja) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
TW202323810A (zh) * 2021-10-08 2023-06-16 日商中外製藥股份有限公司 預填充式注射器製劑的調製方法
TW202337495A (zh) * 2022-01-19 2023-10-01 日商中外製藥股份有限公司 用satralizumab治療自體免疫腦炎

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
KR101314369B1 (ko) * 2008-07-17 2013-10-10 노파르티스 아게 치료학적 항체에 대한 조성물 및 사용 방법
TWI440469B (zh) * 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
SG10201900451SA (en) 2009-03-19 2019-02-27 Chugai Pharmaceutical Co Ltd Pharmaceutical formulation containing improved antibody molecules
TWI457134B (zh) 2009-03-19 2014-10-21 Chugai Pharmaceutical Co Ltd Rheumatoid arthritis treatment
TWI609698B (zh) 2010-01-20 2018-01-01 Chugai Pharmaceutical Co Ltd 穩定化的含抗體溶液製劑
US20130095118A1 (en) * 2011-10-11 2013-04-18 Vaccinex, Inc. Use of Semaphorin-4D Binding Molecules for Modulation of Blood Brain Barrier Permeability
US20170362304A1 (en) * 2014-08-20 2017-12-21 Chugai Seiyaku Kabushiki Kaisha Method for measuring viscosity of protein solution
WO2017179375A1 (ja) 2016-04-15 2017-10-19 国立大学法人山口大学 血液脳関門インヴィトロモデルおよび血液脳関門インヴィトロモデルの作製方法

Also Published As

Publication number Publication date
IL286716A (en) 2021-12-01
EP3949989A4 (en) 2022-12-14
JPWO2020202839A1 (es) 2020-10-08
US20220220210A1 (en) 2022-07-14
CN113660951A (zh) 2021-11-16
BR112021017702A2 (pt) 2021-11-16
CA3133610A1 (en) 2020-10-08
AU2020255449A1 (en) 2021-10-07
WO2020202839A1 (ja) 2020-10-08
TW202102540A (zh) 2021-01-16
KR20210144795A (ko) 2021-11-30
EP3949989A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
MX2021011464A (es) Inhibidor que contiene anticuerpo del receptor anti-interleucina 6 (il-6) para inhibir el deterioro de la funcion de la barrera hemato-encefalica (bbb).
Postow et al. Immune-related adverse events associated with immune checkpoint blockade
US10647770B2 (en) Therapeutic agent for autoimmune diseases comprising PD-1 agonist
KR102193045B1 (ko) 항-cd38 항체 및 레날리도마이드를 포함하는 조성물
Kolesnik et al. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication
JP2017527544A5 (es)
JP2019513726A5 (es)
JP2018515532A5 (es)
US11591406B2 (en) Treatment for multiple myeloma (MM)
Sala et al. Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy
MX2022001065A (es) Anticuerpo anti-bcma, fragmento de union al antigeno y uso medico del mismo.
Araki et al. Neuromyelitis optica spectrum disorders: emerging therapies
US20230197278A1 (en) Multi-variate model for predicting cytokine release syndrome
AU2017234010A1 (en) Methods of treating or preventing graft versus host disease
NZ593312A (en) Remedies for pemphigus containing anti fas ligand antibodies
RU2019143659A (ru) Способы лечения хронического резервуарного илеита
US20200002422A1 (en) Method of preventing graft versus host disease
WO2016102530A1 (en) Cyclic phosphoric acid derivative for the treatment of chronic fatigue syndrome
US10478497B2 (en) Combinations of inecalcitol with an anti-CD38 agent and their uses for treating cancer
Guimarães-Costa et al. Challenges in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy
Jahnz-Różyk et al. Secondary immunodeficiencies–do we need systemic solutions?
KR20240038769A (ko) 항-ilt3 항체를 사용하여 급성 골수성 백혈병을 치료하는 방법
Nair et al. Chronic Inflammatory Demyelinating Polyneuropathy: An Update
RU2020100880A (ru) Способ лечения иммунной тромбоцитопении
RU2018135702A (ru) Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r)